From 6 to 9 April 2019, the XIII World Immune Regulation Meeting (WIRM) was hosted in Davos, Switzerland. The congress gathered top class worldwide researchers in basic and clinical immunology as well as eager students who presented their latest results on immune activation...
April 2019
Evolution of flu-vaccine induced B cell responses
Matsude et al., examined “B cell expansion and evolution after vaccination with replication-competent flu vaccine expressing hemagglutinin (HA) H5 glycoprotein”. They studied both plasma (serum) HA-Ab levels as well as Abs generated from purified influenza-specific (HA) memory B...
Antiviral pathways induced in the RV144 vaccine trial
Gene set enrichment analysis of HIV-envelope stimulated PBMCs revealed that the RV144 vaccine induced genes associated with antigen presentation and antiviral functions. Specifically, Fourati et al., linked IFN-γ responses with reduced risk of HIV acquisition, while NFKB and mTOR...
How are CD8 responses against the malaria liver stage antigens primed ?
Induction of robust and in some cases sterilising CD8 T cell immunity against Plasmodium parasite requires Plasmodium sporozoite infection of hepatocytes, known as the malaria liver stage. As a result, researchers believe that whole cell malaria parasite vaccines...
Contributions to the understanding of the cellular immune response elicited by Brucella canis
Study by Pujol et al., aimed to contribute to a better understanding of the immune-pathogenesis of B. canis, in this work they investigate the CD4+ T cell responses after encountering B. canis-primed MoDCs.
IL-7Rαlo KLRG1hi cells are not always short lived effector cells
Early effectors, short-lived effectors and pre-cursor long term memory cells can be defined as IL-7Rα loKLRG1lo, IL-7Rα loKLRG1hi and IL-7RΑ hiKLRG1lo, respectively. Remmerswaal et al., aimed to determine if IL-7Rα /KLRG1 co-expression profiles and functional features of CD8 memory subsets..
Dual bNAb therapy can maintain HIV viral suppression
Mendoza et al., aimed to determine if a combination of these bNAbs can maintain viral suppression during ATI in HIV-infected individuals. They conducted a Phase 1b trials where 11 ATI individuals were passively immunised with 3 doses of 3BNC117 and 10-1074 bNAbs at 30mg/kg three weeks apart.
A first-in-human antibody–drug conjugate: Hope for patients with advanced solid tumours?
Prior to the study by Professor De Bono and colleagues, no previous study had considered the use of Tisotumab Vedotin, a tissue factor-specific human monoclonal antibody as a treatment option for patients with cancer.